Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Drug-drug interactions of telaprevir and boceprevir in HCV-monoinfected and HIV/HCV-coinfected patients can modify the adherence.

Liver international : official journal of the International Association for the Study of the Liver - 1 May 2015

González-Colominas Elena, Broquetas Teresa, Retamero Alexandra, García-Retortillo Montserrat, Cañete Nuria, Coll Susanna, Pellicer Rosa, Giménez Maria D, Cabrero Beatriz, Bory Felipe, Knobel Hernando, Salas Esther, Solà Ricard, Carrión José A

Abstract excerpt

BACKGROUND & AIMS: The first generation protease inhibitors, boceprevir (BOC) and telaprevir (TVR), are both CYP3A4 inhibitors, which predispose drug-drug interactions (DDIs). The aim of this study was to evaluate the prevalence of potential DDIs, the management of outpatient medication and its impact on adherence and efficacy to antiviral treatment in hepatitis C virus (HCV)-monoinfected and human...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Coinfection
Share to Drug Interactions

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interferon-alpha

Share to Oligopeptides

Share to Polyethylene Glycols

Share to Proline

Share to Protease Inhibitors

Share to Ribavirin

Source

Identifiers

PMID: 25385188
DOI: 10.1111/liv.12729

Genes

BOC

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Drug-drug interactions of telaprevir and boceprevir in HCV-monoinfected and HIV/HCV-coinfected patients can modify the adherence.PMID 25385188Read ↗

Approaches for understanding and predicting drug interactions in human immunodeficiency virus-infected patientsSemantic proximity Read ↗

Telaprevir for the treatment of chronic hepatitis C infection.Semantic proximity Read ↗

Triple therapy with boceprevir or telaprevir for treatment naïve HCV patients.Semantic proximity Read ↗

Prevalence of drug-drug interactions with pangenotypic direct-acting antivirals for hepatitis C and real-world care management in the United States: a retrospective observational study.Semantic proximity Read ↗

Hepatitis C in Brazil: lessons learned with boceprevir and telaprevir.Semantic proximity Read ↗

Telaprevir: a hepatitis C NS3/4A protease inhibitor.Semantic proximity Read ↗

Boceprevir and telaprevir-based triple therapy for chronic hepatitis C: virological efficacy and impact on kidney function and model for end-stage liver disease score.Semantic proximity Read ↗

Safety aspects of protease inhibitors for chronic hepatitis C: adverse events and drug-to-drug interactions.Semantic proximity Read ↗

First-wave protease inhibitors for hepatitis C genotype 1 treatment: a real-life experience in Brazilian patients.Semantic proximity Read ↗

UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients.Semantic proximity Read ↗

Boceprevir: a recently approved protease inhibitor for hepatitis C virus infection.Semantic proximity Read ↗

Therapeutic potential of and treatment with boceprevir/telaprevir-based triple-therapy in HIV/chronic hepatitis C co-infected patients in a real-world setting.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.